GLAUKOS Corp
Glaukos is an ophthalmic pharmaceutical and medical technology company that develops and commercializes therapies for glaucoma, corneal disorders and retinal disease. It sells to ophthalmic surgeons and other eye care professionals, with primary customers including ambulatory surgery centers, hospitals and physician private practices. Its glaucoma products include the iStent family of micro-scale surgical devices and iDose TR, an implant that delivers glaucoma medication inside the eye. Glaukos also sells iLink bio-activated pharmaceutical therapies and associated systems for corneal disorders, including keratoconus. Its other platforms include transdermal pharmaceuticals for anterior segment conditions and sustained-release implants under development for retinal diseases. Glaukos operates in one segment and makes money by selling ophthalmic products and therapies. In the U.S., it sells most products through a direct sales organization; internationally, it uses direct sales subsidiaries and independent distributors. Its corporate headquarters are in Aliso Viejo, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Glaukos Corp. (GKOS) reported Q3 revenue of $211M, up 58% YoY, and raised 2026 guidance to $775M-$785M. The company set a $1B revenue target for 2027, despite potential Medicare coverage restrictions for iDose TR. Shares rose 33% post-earnings. Alignment Healthcare (ALHC) lowered its 2023 adjusted gross profit and EBITDA guidance due to higher medical costs and claims volatility.
Glaukos (GKOS) presented its November 2026 investor deck, projecting 30% revenue growth in 2025. The company highlighted 14 pipeline programs, 12 commercial products, and FDA approvals for iDose TR and Epioxa. As of Q3 2026, Glaukos reported $340M in cash, no debt, and an 88% adjusted gross margin.
Glaukos Corporation and privately-held RevOpsis Therapeutics have partnered to develop and commercialize RO-104, a tri-specific biologic for retinal diseases. Glaukos gains exclusive rights to RO-104 and the RevMod platform for up to four additional retinal candidates. Preclinical data shows RO-104's superior efficacy in animal models compared to approved anti-VEGF therapies, according to RevOpsis. Financial details were not disclosed.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning GKOS (GLAUKOS Corp). Coverage has skewed bearish: 1 bullish, 1 neutral, and 4 bearish.
Recent GKOS coverage spans financial news, insider activity and earnings.
In the last 30 days, GKOS insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($11.3M). The most active reporter was Navratil Tomas, CHIEF DEVELOPMENT OFFICER, with 4 filings.
Shares jumped 33% after the earnings beat and guidance raise.
No new material information; market likely already priced the guidance and cash position.
Glaukos Corporation and privately-held RevOpsis Therapeutics have partnered to develop and commercialize RO-104, a tri-specific biologic for retinal diseases. Glaukos gains exclusive rights to RO-104 and the RevMod platform for up to four additional retinal candidates. Preclinical data shows RO-104's superior efficacy in animal models compared to approved anti-VEGF therapies, according to RevOpsis. Financial details were not disclosed.
Glaukos director Gilbert H. Kliman sold 2,500 shares at $253 each, totaling $632,500. He now owns 37,406 shares, according to an SEC filing.
The insider sale may signal reduced confidence from a director, potentially adding slight downward pressure.
AlphAI scores every news story that mentions GKOS with an AI model for sentiment and relevance, and aggregates insider trades from GLAUKOS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Glaukos Corp. (GKOS) reported Q3 revenue of $211M, up 58% YoY, and raised 2026 guidance to $775M-$785M. The company set a $1B revenue target for 2027, despite potential Medicare coverage restrictions for iDose TR. Shares rose 33% post-earnings. Alignment Healthcare (ALHC) lowered its 2023 adjusted gross profit and EBITDA guidance due to higher medical costs and claims volatility.
Glaukos (GKOS) presented its November 2026 investor deck, projecting 30% revenue growth in 2025. The company highlighted 14 pipeline programs, 12 commercial products, and FDA approvals for iDose TR and Epioxa. As of Q3 2026, Glaukos reported $340M in cash, no debt, and an 88% adjusted gross margin.
Glaukos Corporation and privately-held RevOpsis Therapeutics have partnered to develop and commercialize RO-104, a tri-specific biologic for retinal diseases. Glaukos gains exclusive rights to RO-104 and the RevMod platform for up to four additional retinal candidates. Preclinical data shows RO-104's superior efficacy in animal models compared to approved anti-VEGF therapies, according to RevOpsis. Financial details were not disclosed.
Glaukos director Gilbert H. Kliman sold 2,500 shares at $253 each, totaling $632,500. He now owns 37,406 shares, according to an SEC filing.
Kliman Gilbert H sold 2,500 shares of GLAUKOS Corp (GKOS) at $253.00 ($0.63M total) on 2026-11-04.
Berkshire Hathaway acquired $26.9M in Sirius XM shares (SIRI) at $28.89-$30.23. Stride (LRN) director bought $17.57M in shares. Boeing (BA) directors purchased shares near 52-week low. SiteOne (SITE) CEO bought $1.004M in stock. Arista (ANET) director sold $45.8M in shares. Dover (DOV), American Express (AXP), Glaukos (GKOS), and Rocket Lab (RKLB) insiders also reported sales.
Glaukos (GKOS) Chief Development Officer Tomas Navratil sold 44,436 shares for $10.6M at an average price of $238.97 on Oct 30, 2026. He also exercised 12,969 options at $75.97 each, leaving him with 37,328 shares directly held.
Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 44,436 shares of GLAUKOS Corp (GKOS) at an average of $238.97 ($237.54–$240.52, $10.62M total) across 4 trades on 2026-10-30.
McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.
JP Morgan kept its Overweight rating on Glaukos and increased its price target to $240 from $200, a 20% rise. The new target suggests a 1% downside from the Oct 29 close of $242.48. Recent analyst targets for Glaukos range from $225 to $255.
